Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Artelac Complete MDO vs VISMED MULTI in Moderate to Severe Dry Eye Disease
NCT07593885Recruiting
- Sponsor
- Dr Gerhard Mann
- Start
- Apr 2026
- Primary completion
- Nov 2026
- Modality
- Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
Randomised, double-blind trial of Artelac Complete MDO in dry eye disease (DED) (2 arms), sponsored by Dr Gerhard Mann. Primary endpoint: Ocular Surface Disease Index at 90 days. Started Apr 2026; status: recruiting.
02
Drugs
Artelac Complete MDO
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT07593885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07593885.